Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.98% $7.42
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 402.91 mill |
EPS: | 2.97 |
P/E: | 2.50 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 54.30 mill |
Avg Daily Volume: | 0.643 mill |
RATING 2024-04-25 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 2.50 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.43x |
Company: PE 2.50 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 6.78 - 8.06 ( +/- 8.68%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ferguson Toby | Buy | 105 000 | Common Stock |
2024-04-02 | Swartz Robin | Sell | 1 357 | Common Stock |
2024-04-02 | Sandrock Alfred | Sell | 12 115 | Common Stock |
2024-03-25 | Ferguson Toby | Buy | 210 000 | Stock Option (Right to Buy) |
2024-03-25 | Ferguson Toby | Buy | 0 |
INSIDER POWER |
---|
44.34 |
Last 94 transactions |
Buy: 7 546 876 | Sell: 3 757 926 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.42 (-1.98% ) |
Volume | 0.521 mill |
Avg. Vol. | 0.643 mill |
% of Avg. Vol | 80.96 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $7.44 | N/A | Active |
---|
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.